Daiichi Sankyo To Apply Prasugrel For PCI-ACS Patients
This article was originally published in PharmAsia News
Executive Summary
Daichi Sankyo announced Sept. 21 it “achieved the desired results” in its Phase III trials with the anti-platelet drug prasugrel, and said that it would apply for approval of the drug in Japan in 2013. The